Clinical Trials Logo

Filter by:
NCT ID: NCT01929655 Completed - Prostatic Neoplasms Clinical Trials

Japanese BAY88-8223 Monotherapy Phase II Study

Start date: September 30, 2013
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of the best standard of care plus BAY88-8223 in Japanese patients with CRPC and bone metastases after a multiple administration

NCT ID: NCT01929486 Active, not recruiting - Solid Tumor Clinical Trials

Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer.

Start date: February 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate safety, pharmacokinetics, effect of regulatory T cell depletion with Mogamulizumab for advanced or recurrent cancer patients.

NCT ID: NCT01929473 Recruiting - Pertussis Infection Clinical Trials

Seroepidemiological Study of Pertussis and Other Infectious Diseases

Start date: September 2013
Phase: N/A
Study type: Observational

Serum samples will be corrected twice from the same youth subjects with one year interval. Seroincidence of pertussis will be estimated by the elevation of Ig-G-PT in paired sera from an identical individual. The relationship between the incidence and the demographic data or medical history of the subjects will be discussed.

NCT ID: NCT01929317 Terminated - Parkinson Disease Clinical Trials

A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.

Start date: August 28, 2013
Phase: Phase 3
Study type: Interventional

This study is a Phase III, multicentre, randomized, initial double-blind study with subsequent open label phases. The study will havea screening phase (4 weeks), a dose increase effect verification phase (12 weeks), a down titration 1 phase (1 week), a long-term phase (39 weeks), down titration 2 phase (1 to 2 weeks) and a follow up phase. Subjects will be assigned to Ropinirole CR high-dose group or Ropinirole CR maintenance group at a ratio of 3:1. This study is being conducted to evaluate the efficacy (effect of increasing Ropinirole dose from 16 mg/day to 18-24 mg/day) of the Ropinirole CR tablets in early and advanced PD patients who have not achieved an optimal therapeutic response with marketed Ropinirole Immediate release (IR) (15 mg/day) or marketed Ropinirole CR (16 mg/day) formulations.

NCT ID: NCT01928940 Completed - Solid Tumours Clinical Trials

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Start date: August 15, 2013
Phase: Phase 2
Study type: Interventional

This is a Japanese Phase I/II, open-label, non-controlled study to evaluate the safety, tolerability, pharmacokinetic profile, and efficacy of the combination of GSK2118436 and GSK1120212 in subjects with BRAF V600E/K mutation positive advanced solid tumors (Phase I part) and BRAF V600E/K mutation positive cutaneous melanoma (Phase II part).

NCT ID: NCT01927861 Completed - Genetic Disorder Clinical Trials

Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome

Start date: August 19, 2013
Phase: Phase 3
Study type: Interventional

This trial is conducted in Asia. The aim of the trial is to investigate the long-term efficacy and safety of two doses of NN-220 (somatropin) in short stature due to Noonan syndrome.

NCT ID: NCT01927263 Completed - Clinical trials for Rheumatoid Arthritis

A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis

Start date: July 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate similarity between NI-071 and infliximab(the comparator) in terms of efficacy in patients with Rheumatoid Arthritis not adequately responding to Methotrexate.

NCT ID: NCT01927250 Completed - Healthy Clinical Trials

Influence of Multi-dimensional Wellness Program on Quality of Life

MDWP
Start date: February 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether multi-dimensional wellness program (diet, art and biofield therapy) influences the quality of life for those with different health status in Japan.

NCT ID: NCT01925274 Terminated - Clinical trials for Metastatic Colorectal Cancer

A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Start date: November 15, 2013
Phase: Phase 2
Study type: Interventional

This study will investigate whether the combination of PF-05212384 plus Irinotecan improves progression free survival in patients with KRAS and NRAS wild type metastatic colorectal cancer when compared with the combination of cetuximab plus Irinotecan. A Japanese Lead in Cohort will assess the safety of the combination of PF-05212384 + irinotecan in patients enrolled at Japanese sites.

NCT ID: NCT01925209 Completed - Clinical trials for Sporadic Inclusion Body Myositis

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients

RESILIENT
Start date: September 26, 2013
Phase: Phase 2/Phase 3
Study type: Interventional

This study evaluated the efficacy, safety and tolerability of multiple doses of bimagrumab/BYM338 vs placebo, when administered intravenously (i.v.), on physical function, muscle strength, and mobility in patients with sporadic inclusion body myositis (sIBM).